Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vivus: into single digits -- Ignore unavailable to you. Want to Upgrade?

To: BDR who wrote (131)	3/16/1998 2:02:00 AM
From: BDR	Respond to of 1016

Thoughts on the idea that Viagra will expand the impotence market and those that fail Viagra will then turn to MUSE. Could happen, but PFE will market Viagra to family docs and internists not urologists. The additional patients attracted to a pill are not currently interested in suppositories or injections or they would be using them now. When the new patients go to their FP, try Viagra and fail as surely some (many?) will, how many are going to go on to try what they have already decided they don't want? How many FPs or internists are going to be prescribing MUSE or Caverject? Not many now. Not many in the future. Since the two drugs seem to treat different presentations of impotence Viagra may have no further negative effects on VVUS (41 to 11 is enough) but it may also not have as much positive effect as the longs hope.